Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia

IONIS PHARMACEUTICALS INC

Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).
Met all key secondary endpoints; majority of participants achieved normal TG <150 mg/dL.
Favorable safety profile; most common AE was mild injection site reactions.
Study enrolled 1,478 participants with moderate HTG on standard-of-care lipid-lowering therapy.
Pivotal Phase 3 CORE and CORE2 data in sHTG expected Q3 2025; potential sNDA filing by year-end.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.